BlueRidge Life Sciences Enhances Pathology Services with Industry-Leading Experts
BlueRidge Life Sciences (BRLS), a leading provider of scientific and regulatory consulting solutions, today announced the expansion of its capabilities in pathology services with the addition of industry leaders Dr. Thomas M. Monticello, DVM, Ph.D., DACVP, and Dr. Nathaniel D. Collins, DVM, Ph.D., DACVP, to its ToxStrategies division. Dr. Collins and Dr. Monticello bring decades of combined expertise in nonclinical safety sciences, toxicology, and pathology.
Dr. Monticello joins BRLS with over 30 years of leadership experience in nonclinical safety sciences and translational toxicology/pathology across major global pharmaceutical companies. A board-certified veterinary pathologist, he has extensive expertise in regulatory toxicology and health authority interactions spanning IND, NDA, and BLA applications. He has also served as Past President of the Society of Toxicologic Pathology and held leadership positions in the International Consortium for Innovation and Quality in Pharmaceutical Research (IQ), including as Chair of its DruSafe Leadership Group.
Dr. Collins brings 25 years of experience across pathology, immunotoxicology, investigative toxicology, and genetic toxicology, most recently serving as Vice President for Nonclinical Safety at a major pharmaceutical company. In that role, he led a global team of 35 toxicologists and managed nonclinical strategy, data interpretation, and regulatory interactions with international health authorities. A board-certified veterinary clinical pathologist, Dr. Collins has contributed to the development and approval of numerous marketed therapies across oncology, immunology, neurology, virology, and cardiovascular disease.
“We are thrilled to welcome Dr. Monticello and Dr. Collins to the BlueRidge Life Sciences team,” said Ian Kelly, CEO at BRLS. “Their deep expertise and leadership in nonclinical safety and toxicology will further strengthen our ability to guide clients through complex scientific and regulatory challenges at every stage of product development.”
The addition of Drs. Monticello and Collins show BRLS’ commitment to providing world-class expertise in pharmaceutical and biopharmaceutical development, enhancing its capabilities to support clients in achieving safe, effective, and timely therapeutic solutions.
About BlueRidge Life Sciences
BlueRidge Life Sciences (BRLS), is a growing family of companies providing a comprehensive suite of life sciences services, spanning toxicology, regulatory science, risk assessment, epidemiology, biostatistics, engineering, clinical research, health economics, pharmaceutical commercialization, and environmental consulting. Across these specialized areas, BRLS collaborates to deliver science-driven solutions that support industries including pharmaceuticals, biotechnology, medical devices, chemicals, foods and consumer products. The collective BRLS’ expertise helps clients navigate regulatory requirements, assess safety and efficacy, manage risks, and optimize pharmaceutical commercialization strategies. For more information, please visit blueridgelifesciences.com.